BTK Inhibitor Therapy: A Guide for Patients and Their Caregivers on Avoiding and Managing Side Effects

Download this accessible resource developed for patients and caregivers on side effect care when receiving acalabrutinib, ibrutinib, or zanubrutinib.
Anthony Perissinotti, PharmD, BCOP
Format: Adobe Acrobat (.pdf)
File Size: 486 KB
Released: August 25, 2021

Information on this Educational Activity


Anthony Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
Clinical Team Leader
, Hematology/Oncology
Adjunct Clinical Assistant Professor
University of Michigan, Michigan Medicine
Roger Cancer Center
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP, has disclosed that he has received consulting fees from Amgen, Pfizer, and Servier.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
BeiGene, Ltd.

Related Content

Download these expert-selected slides from Clinical Care Options (CCO) on acute myeloid leukemia to help provide optimal treatment for your patients with AML.

Amir T. Fathi, MD Eunice S. Wang, MD Released: October 21, 2021

Shaji Kumar, MD, and Beth Faiman, PhD, share expert guidance on diagnosing and managing patients with AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: October 21, 2021 Expired: October 20, 2022

Downloadable slideset on diagnosing and managing AL and ATTR amyloidosis, from Clinical Care Options (CCO)

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Released: October 21, 2021

Prof. Paul Coppo shares his thoughts on the current management of aTTP using clinical guidelines, biomarkers, and targeted therapies, from Clinical Care Options (CCO)

person default Paul Coppo, MD, PhD Released: October 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.